Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

US pharma giant Merck & Co (NYSE: MRK) has presented positive results from two pivotal Phase III trials of the ...

Fintel reports that on March 14, 2025, B of A Securities downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

Merck and the plaintiff plan to reconvene in ... a professor at UC Law San Francisco who specializes in legal and policy issues related to vaccines. Robi, 30, was vaccinated with Gardasil as ...

being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025. In the double ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Exclusive-Merck Vaccine Case Linked to HHS Secretary ... a professor at UC Law San Francisco who specializes in legal and policy issues related to vaccines. Robi, 30, was vaccinated with Gardasil ...

(Reuters) - Merck and a woman suing the drugmaker agreed to halt a ... to want a delay," said Dorit Reiss, a professor at UC Law San Francisco who specializes in legal and policy issues related to ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

(Reuters) - Merck (NSE:PROR) and a woman suing the drugmaker ... a professor at UC Law San Francisco who specializes in legal and policy issues related to vaccines. Robi, 30, was vaccinated ...